Correlation Between Cyclacel Pharmaceuticals and AN2 Therapeutics
Can any of the company-specific risk be diversified away by investing in both Cyclacel Pharmaceuticals and AN2 Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cyclacel Pharmaceuticals and AN2 Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Cyclacel Pharmaceuticals and AN2 Therapeutics, you can compare the effects of market volatilities on Cyclacel Pharmaceuticals and AN2 Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cyclacel Pharmaceuticals with a short position of AN2 Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cyclacel Pharmaceuticals and AN2 Therapeutics.
Diversification Opportunities for Cyclacel Pharmaceuticals and AN2 Therapeutics
-0.45 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Cyclacel and AN2 is -0.45. Overlapping area represents the amount of risk that can be diversified away by holding Cyclacel Pharmaceuticals and AN2 Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on AN2 Therapeutics and Cyclacel Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cyclacel Pharmaceuticals are associated (or correlated) with AN2 Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of AN2 Therapeutics has no effect on the direction of Cyclacel Pharmaceuticals i.e., Cyclacel Pharmaceuticals and AN2 Therapeutics go up and down completely randomly.
Pair Corralation between Cyclacel Pharmaceuticals and AN2 Therapeutics
Given the investment horizon of 90 days Cyclacel Pharmaceuticals is expected to under-perform the AN2 Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Cyclacel Pharmaceuticals is 1.09 times less risky than AN2 Therapeutics. The stock trades about -0.16 of its potential returns per unit of risk. The AN2 Therapeutics is currently generating about 0.03 of returns per unit of risk over similar time horizon. If you would invest 210.00 in AN2 Therapeutics on September 1, 2024 and sell it today you would lose (43.00) from holding AN2 Therapeutics or give up 20.48% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Cyclacel Pharmaceuticals vs. AN2 Therapeutics
Performance |
| Timeline |
| Cyclacel Pharmaceuticals |
| AN2 Therapeutics |
Cyclacel Pharmaceuticals and AN2 Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Cyclacel Pharmaceuticals and AN2 Therapeutics
The main advantage of trading using opposite Cyclacel Pharmaceuticals and AN2 Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cyclacel Pharmaceuticals position performs unexpectedly, AN2 Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AN2 Therapeutics will offset losses from the drop in AN2 Therapeutics' long position.| Cyclacel Pharmaceuticals vs. Eliem Therapeutics | Cyclacel Pharmaceuticals vs. Ikena Oncology | Cyclacel Pharmaceuticals vs. Ovid Therapeutics | Cyclacel Pharmaceuticals vs. Connect Biopharma Holdings |
| AN2 Therapeutics vs. Aerovate Therapeutics | AN2 Therapeutics vs. Adagene | AN2 Therapeutics vs. Acrivon Therapeutics, Common | AN2 Therapeutics vs. Rezolute |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Complementary Tools
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |